<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03441113</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-352-4365</org_study_id>
    <secondary_id>2017-004350-42</secondary_id>
    <nct_id>NCT03441113</nct_id>
  </id_info>
  <brief_title>Extended Access of Momelotinib in Adults With Myelofibrosis</brief_title>
  <official_title>Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to provide extended access of momelotinib (MMB) in
      participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential
      thrombocythemia myelofibrosis (Post-PV/ET MF) enrolled in Gilead sponsored studies
      GS-US-352-0101 (NCT01969838), GS-352-1214 (NCT02101268), GS-US-352-1154 (NCT02124746), who
      are currently receiving treatment with MMB (available as 100 mg, 150 mg and 200 mg tablets)
      and have not experienced progression of disease.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 3, 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Had Access to, and Received the Intervention</measure>
    <time_frame>Up to 96 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Post-polycythemia Vera Myelofibrosis (Post-PV MF)</condition>
  <condition>Primary Myelofibrosis (PMF)</condition>
  <condition>Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Study GS-US-352-0101</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-0101 for a maximum duration of 96 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Study GS-US-352-1214</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1214 for a maximum duration of 96 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Study GS-US-352-1154</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1154 for a maximum duration of 96 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMB</intervention_name>
    <description>Tablet(s) administered orally once daily</description>
    <arm_group_label>Cohort 1: Study GS-US-352-0101</arm_group_label>
    <arm_group_label>Cohort 2: Study GS-US-352-1214</arm_group_label>
    <arm_group_label>Cohort 3: Study GS-US-352-1154</arm_group_label>
    <other_name>GS-0387</other_name>
    <other_name>CYT387</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Currently enrolled in Studies GS-US-352-0101, GS-US-352-1214, or GS-US-352-1154

          -  Able to comprehend and willing to sign the informed consent form

        Key Exclusion Criteria:

          -  Known hypersensitivity to MMB, its metabolites, or formulation excipients

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Agnes Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2018</study_first_submitted>
  <study_first_submitted_qc>February 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2018</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

